KeraCure, Inc. announced today that the first patients have been treated in a Multi-Center Pivotal Study for the treatment of diabetic foot ulcers. The study was recently approved by the Food and Drug Administration (FDA) to test the safety and efficacy of the KeraPac(TM) device in approximately 270 subjects in 16 clinical sites across the U.S. The Company expects to complete enrollment in approximately one year. Its proprietary platform technology was developed at the University of Michigan School of Medicine and Wayne State University .